Alkermes Analyst Ratings
MDMA Therapy For PTSD Faces FDA Delay: Are There Other Ways Forward?
Incannex Secures $60M Financing To Drive Advances In Psychedelic And Cannabinoid Therapies
Irish Biotech Firm GH Research Sees Cash Decline in Q2, Advances Psychedelic Drug Trials
GH Research Analyst Ratings
GH Research Q2 2024 GAAP EPADS $(0.20) Beats $(0.23) Estimate, Cash Balance Of $204.5M
ADVISORSHARES PSYCHEDELICS ETF To Carry Out 1-for-10 Reverse Stock Split On September 10th, 2024
AdvisorShares Announces 1-For-10 Reverse Split Of ETF, Effective September 10, 2024
Mind Medicine Analyst Ratings
Galapagos, XPeng, CorMedix And Other Big Stocks Moving Higher On Monday
Clearmind Medicine Shares Are Trading Higher After the Company Announced It Received a Patent Approval From the US Patent and Trademark Office.
Clearmind Medicine Receives New Patent Approval From US Patent And Trademark Office, Marking Significant Advancement In Its Proprietary MEAI-Based Binge Behavior Regulator Program
Lykos Laying off 75% of Workforce Following FDA Rejection of Psychedelic Drug for PTSD
Earnings Call Summary | VistaGen Therapeutics(VTGN.US) Q1 2025 Earnings Conference
Mind Medicine (MindMed) Inc. (MNMD) Q2 2024 Earnings Call Transcript Summary
Here's the Major Earnings After the Close Today
Here Is the Next Potential Market Catalyst
VistaGen Therapeutics Q1 2025 Earnings Preview
Psychedelics Company MindMed Prices Public Offering Aiming To Raise $75M
Medical Journal Retracts Three Articles Related to MDMA for PTSD